# US 2022/0064123 A1 · (--)-Huperzine A Processes and Related Compositions and Methods of Treatment

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0064123 A1
- Document ID: US20220064123A1
- Status: Published application
- Kind: A1
- Application number: 17/482,996
- Filed: 2021-09-23
- Published: 2022-03-03
- Earliest claimed: 2011-03-04
- Assignees: Yale University
- Applicants: Yale University
- Inventors: Seth Herzon; Maung Kyaw Moe Tun
- Web page: https://patentgrep.com/patent/US20220064123A1

## CPC

- C07D 221/22: Bridged ring systems
- A61K 31/439: the ring forming part of a bridged ring system, e.g. quinuclidine (8-azabicyclo [3.2.1] octanes A61K31/46)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 21/02: Muscle relaxants, e.g. for tetanus or cramps
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/22: Anxiolytics
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 25/32: Alcohol-abuse
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 39/02: Antidotes
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07F 7/10: containing nitrogen {having a Si-N linkage}
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)

## Abstract

The invention provides (1) processes for making substantially-pure (−) huperzine A and substantially-pure (−) huperzine A derivatives; (2) compositions useful in making substantially-pure (−) huperzine A and substantially-pure (−) huperzine A derivatives; and (3) methods of treating or preventing neurological disorders using substantially-pure (−) huperzine A and substantially-pure (−) huperzine A derivatives.

## Claims

### Claim at position 1

1-12. (canceled)

### Claim 13

A compound of the formula (I):
wherein:
R1 is selected from the group consisting of substituted or unsubstituted C1-C6 alkyl and substituted or unsubstituted ether;
R2 and R5 are independently selected from the group consisting of H, substituted or unsubstituted C1-C6 alkyl, and CN, provided that when one of R2 or R5 is CN, the other must be H;
X is halogen;
R3 at each occurrence is independently selected from the group consisting of H, substituted or unsubstituted C1-C6 alkyl, ether, amino, and alkoxy;
R4 is selected from the group consisting of Si(CH3)2Ph, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkenyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl;
A is C, N, or S;
m is 0, 1, or 2;
n is 0 or 1;
or a pharmaceutically acceptable salt, enantiomer, diasteromer, solvate or polymorph thereof.

### Claim 14 (depends on 13)

The compound of claim 13, or a pharmaceutically acceptable salt, enantiomer, diastereomer, solvate or polymorph thereof, wherein the compound is:

### Claim at position 4

15-44. (canceled)
